The Immune Repertoire Sequencing Market analyses B-cell and T-cell receptor diversity to enhance immunotherapy, vaccine research, and personalised medicine. It is rapidly growing, fueled by high-throughput sequencing and AI analytics.
According to FutureWise analysis, the Immune Repertoire Sequencing Market in 2026 is US$377.25 million and is expected to reach US$715.8 million by 2036 at a CAGR of 6.61%. This market is expanding due to rising applications in cancer immunotherapy, autoimmune disease research, and vaccine development. Immune repertoire sequencing provides detailed profiling of B- and T-cell receptors, offering key insights into immune responses and supporting precision medicine efforts.
Growth Drivers:
- Rising demand for personalised medicine and targeted immunotherapies.
- Increasing use of high-throughput sequencing technologies.
- Growing prevalence of infectious and autoimmune diseases.
- Expansion of vaccine development and research programs.
- Integration of AI and bioinformatics for immune profiling.
Key Trends:
- Growing adoption of single-cell immune profiling for precise analysis.
- Integration of AI and machine learning for advanced immune data interpretation.
- Expansion in cancer immunotherapy and personalised treatment applications.
- Increasing use in infectious disease monitoring and vaccine development.
- Rising collaborations between biotech firms and research institutes for innovative solutions.
Market Segmentation and Key Players:
The Immune Repertoire Sequencing Market is segmented by product into instruments (such as NGS and PCR), assay kits and reagents (including human and mouse TCR/BCR kits), analytical software for TCR/BCR data analysis, and services (such as sequencing and data analysis). Applications cover biomarker discovery, cancer immunotherapy, infectious disease research, autoimmune and allergy studies, vaccine development, and immunodeficiency identification. End users include diagnostic laboratories, pharmaceutical & biotech companies, and research institutes, while regions span North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. Comprehensive segmentation details are provided in the Segmentation section below.
Major companies operating in the Immune Repertoire Sequencing Market include ILLUMINA, Inc. and Thermo Fisher Scientific.
Research Methodology:
FutureWise Research employs a mixed methodology for the Immune Repertoire Sequencing Market, combining primary and secondary research. Primary research entails interviews with industry experts and executives from biotech, pharmaceutical, and diagnostic companies to gain insights on market trends and strategies. Secondary research encompasses analysing reports, scientific publications, and industry journals to validate data and identify patterns.